BioAsset

Insights / All articles

Company Analysis

$6.7B: Merck’s Leukemia Drug Acquisition That Could Shake Up The Market

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides

Merck announced last week that it is acquiring Terns Pharmaceuticals for $53 a share in a roughly $6.7B deal, and the asset at the center of it is worth paying close attention to.

TERN-701, a tyrosine kinase inhibitor developed by Terns, is an oral targeted therapy for chronic myeloid leukemia, currently in early-stage trials. Early data presented at the American Society of Hematology last year showed improvements in both efficacy and safety over existing options, with the potential for once-a-day dosing. That puts it on a direct collision course with Novartis’ Scemblix, a drug projected to hit $4B+ in peak annual sales. Merck is not simply acquiring a pipeline asset. It is making a calculated move to challenge one of pharma’s most formidable franchises. Novartis scaled Scemblix into a dominant market position remarkably quickly, and Merck’s willingness to compete directly signals strong belief in TERN-701’s potential.

Who else is at risk

Besides Scemblix, a few other drugs are on the radar after this acquisition. Scemblix (asciminib) carries the highest risk, as the direct competitor for first-line CML, because TERN-701’s dosing and tolerability profile attacks its biggest vulnerability. Pfizer’s Bosulif (bosutinib) and Bristol Myers Squibb’s Sprycel (dasatinib) carry moderate risk: these older second-generation inhibitors are already losing share to Scemblix, and further damage is likely if TERN-701 advances. Novartis’ Gleevec faces the least risk, since the generic version is a cheaper option and TERN-701 targets patients seeking superior efficacy despite the price.

The global CML market is about $5.8B annually and growing. A drug with best-in-class efficacy and tolerability could capture 25-35% market share within five years of approval. That is $1.5-2B in peak annual sales for Merck.

Merck’s buying spree

In the last two years, Merck has spent around $25B purchasing smaller companies. It bought Cidara Therapeutics in 2025 for $9.2B, for the preventive antifungal rezafungin, which addresses hospital-acquired infections and diversifies the company beyond oncology. It bought Verona Pharma in 2025 for $10B, for ensifentrine in COPD, the first new mechanism in pulmonary disease in decades and another non-oncology anchor. And now it is buying Terns in 2026 for $6.7B, bringing it back to oncology but targeting a different mechanism than Keytruda’s checkpoint inhibition.

The reason for the spree is straightforward. Keytruda generated over $25B in 2024 and is Merck’s single largest revenue driver, but its core patents expire later this decade. CEO Rob Davis has called the result the “broadest pipeline” in the company’s recent history, targeting $70B in annual revenue next decade.

Three possible scenarios

In the bull case, TERN-701 reaches $1.8-2.4B in peak sales. Phase 3 confirms a best-in-class profile, the drug displaces Scemblix in first-line treatment, and Merck expands significantly.

In the base case, peak sales land at $800M-$1.2B. Phase 3 data is solid and the drug is approved in second-line CML, capturing patients who discontinue Scemblix. It competes but does not dethrone, and still validates the $6.7B price tag.

The main risk is a bidding war. The deal included a 6% closing premium, paying $53 a share when the market had shares at $50, which is unusually low. For reference, a typical biotech acquisition premium ranges from 30% to 100% above the current share price. AbbVie and BMS are logical suitors. If a competing bid emerges before the shareholder vote, Merck may have to raise the offer.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.